Scope of report
- The report provides a snapshot of the global therapeutic landscape of Gilles de la Tourette’s syndrome.
- The report assesses Gilles de la Tourette’s syndrome pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Gilles de la Tourette’s syndrome pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Gilles de la Tourette’s syndrome ranging from discovery to pre-registration and undisclosed stages.
Otsuka Pharmaceutical, Carlsson Research AB, Pfizer, Afecta Pharmaceuticals, Northwestern University, AstraZeneca, Synchroneuron, Abide Therapeutics, Therapix Biosciences, Schering-Plough, LifeHealth Limited, Neurocrine Biosciences, Janssen L.P., Boehringer Ingelheim, Reviva Pharmaceuticals, Auspex Pharmaceuticals, Allergan
Aripiprazole, Seridopidine, PF 3654746, Vigabatrin, AFX 221, CPP 115, AZD 5213, Acamprosate, ABX 1431, THX TS01, Ecopipam, Tetrabenazine, Valbenazine, Risperidone, Pramipexole, Botulinum toxin A, Vatiquinone, RP 5063, Deutetrabenazine, Botulinum toxin A injectable
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800